Literature DB >> 21607032

Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study.

M Raptopoulou, G Touloumi, D Tzourmakliotis, G Nikolopoulou, M Dimopoulou, G Giannoulis, T Vasiliadis, A Skoutelis, O Anagnostou, G Hatzis, S Manolakopoulos.   

Abstract

BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is an important health problem worldwide. The aim of the study is to describe the baseline characteristics and possible epidemiological changes of the patients with chronic HCV infection included in a nationwide Greek study. PATIENTS AND METHODS: two thousand eight hundred seventeen (2817) patients, followed-up at 20 hepatology centres throughout Greece between the years 1997 and 2006 were enrolled in the study.
RESULTS: Intravenous drug use (IDU) and history of blood transfusion prior to 1992 was reported in 30.7% and 22.6% of our patients, respectively. In 1865 (66.2%) patients with known genotypes, the distribution for genotype 1, 2, 3 and 4 was 45.1%, 7%, 34% and 13.9% respectively. Genotype 1 was more common in older people, in women (55.9% p<0.001) and patients with transfusion-related hepatitis (61.6% p<0.001). Genotype 3 was more common in younger patients, in men (43% p<0.001) and in IDUs (63.3% p<0.001). A significant reduction of transfusion-related hepatitis C incidence (p<0.001) in conjunction with the proportion of genotype 1 (p<0.001) was observed during the last three decades while an increase in IDU infected patients and genotype 3 was detected.
CONCLUSIONS: Our study showed a significant change in HCV genotype distribution and source of HCV infection during the last three decades and under that scope, urgent actions are needed in order to control the spread of HCV infection.

Entities:  

Keywords:  Greece; HCV genotypes; hepatitis C epidemiology; intravenous drug use; transfusion

Year:  2011        PMID: 21607032      PMCID: PMC3093141     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  15 in total

1.  HCV infection in the general population of a Greek island: prevalence and risk factors.

Authors:  C Goritsas; I Plerou; S Agaliotis; R Spinthaki; K Mimidis; D Velissaris; N Lazarou; C Labropoulou-Karatza
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

2.  Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy.

Authors:  Gianna Dal Molin; Filippo Ansaldi; Claudia Biagi; Pierlanfranco D'Agaro; Manola Comar; Lory Crocè; Claudio Tiribelli; Cesare Campello
Journal:  J Med Virol       Date:  2002-11       Impact factor: 2.327

3.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

4.  The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a.

Authors:  K A Harris; C Gilham; P P Mortimer; C G Teo
Journal:  J Med Virol       Date:  1999-06       Impact factor: 2.327

5.  Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece.

Authors:  S P Savvas; J Koskinas; C Sinani; A Hadziyannis; F Spanou; S J Hadziyannis
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

6.  Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.

Authors:  V Sypsa; G Touloumi; G V Papatheodoridis; N C Tassopoulos; I Ketikoglou; I Vafiadis; G Hatzis; D Tsantoulas; E Akriviadis; S Koutsounas; A Hatzakis
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

7.  A survey of bloodborne viruses and associated risk behaviours in Greek prisons.

Authors:  M Malliori; V Sypsa; M Psichogiou; G Touloumi; A Skoutelis; N Tassopoulos; A Hatzakis; C Stefanis
Journal:  Addiction       Date:  1998-02       Impact factor: 6.526

8.  Infection with hepatitis C virus genotype 4 in the United States.

Authors:  Andre C Lyra; Sunil Ramrakhiani; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  J Clin Gastroenterol       Date:  2004-01       Impact factor: 3.062

9.  Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece.

Authors:  C A Gogos; K P Fouka; G Nikiforidis; K Avgeridis; G Sakellaropoulos; H Bassaris; A Maniatis; A Skoutelis
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates.

Authors:  A Katsoulidou; V Sypsa; N C Tassopoulos; J Boletis; A Karafoulidou; I Ketikoglou; D Tsantoulas; I Vafiadi; G Hatzis; A Skoutelis; E Akriviadis; T Vasiliadis; G Kitis; G Magiorkinis; A Hatzakis
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

View more
  12 in total

1.  Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Authors:  O Anagnostou; S Manolakopoulos; G Bakoyannis; G Papatheodoridis; A Zisouli; M Raptopoulou-Gigi; E Manesis; I Ketikoglou; G Dalekos; C Gogos; T Vassiliadis; D Tzourmakliotis; S Karatapanis; S Kanatakis; - Zoumpoulis; A Hounta; S Koutsounas; G Giannoulis; N Tassopoulos; G Touloumi
Journal:  Hippokratia       Date:  2014-01       Impact factor: 0.471

Review 2.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

3.  Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 2.566

4.  The "hidden" epidemic: a snapshot of Moroccan intravenous drug users.

Authors:  Roxana-Delia Trimbitas; Fatima Zahra Serghini; Fatiha Lazaar; Warda Baha; Abderrahim Foullous; Mohammed Essalhi; Abdelouahed El Malki; Abdelkrim Meziane Bellefquih; Abdelouaheb Bennani
Journal:  Virol J       Date:  2014-03-06       Impact factor: 4.099

Review 5.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

6.  Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.

Authors:  Josefine Ederth; Camilla Jern; Helené Norder; Lars Magnius; Erik Alm; Björg Kleverman Rognsvåg; Carl-Gustaf Sundin; Mia Brytting; Joakim Esbjörnsson; Mattias Mild
Journal:  Infect Ecol Epidemiol       Date:  2016-02-05

7.  Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.

Authors:  Roman Chlibek; Jan Smetana; Renata Sosovickova; Peter Gal; Petr Dite; Vlasta Stepanova; Lenka Pliskova; Stanislav Plisek
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

Review 8.  Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region.

Authors:  M C Liberto; N Marascio; E Zicca; G Matera
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090

Review 9.  Epidemiology of hepatitis C in Greece.

Authors:  Christos Triantos; Christos Konstantakis; Paraskeui Tselekouni; Maria Kalafateli; Ioanna Aggeletopoulou; Spilios Manolakopoulos
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

Review 10.  Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: A systematic review and meta-analysis.

Authors:  Rossella Letizia Mancusi; Massimo Andreoni; Daniela d'Angela; Cesare Sarrecchia; Federico Spandonaro
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.